Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.

The prognostic impact of minimal residual disease (MRD) was analyzed in 259 patients with mantle cell lymphoma (MCL) treated within 2 randomized trials of the European MCL Network (MCL Younger and MCL Elderly trial). After rituximab-based induction treatment, 106 of 190 evaluable patients (56%) achieved a molecular remission (MR) based on blood and/or bone marrow (BM) analysis. MR resulted in a significantly improved response duration (RD; 87% vs 61% patients in remission at 2 years, P = .004) and emerged to be an independent prognostic factor for RD (hazard ratio = 0.4, 95% confidence interval, 0.1-0.9, P = .028). MR was highly predictive for prolonged RD independent of clinical response (complete response [CR], complete response unconfirmed [CRu], partial response [PR]; RD at 2 years: 94% in BM MRD-negative CR/CRu and 100% in BM MRD-negative PR, compared with 71% in BM MRD-positive CR/CRu and 51% in BM MRD-positive PR, P = .002). Sustained MR during the postinduction period was predictive for outcome in MCL Younger after autologous stem cell transplantation (ASCT; RD at 2 years 100% vs 65%, P = .001) and during maintenance in MCL Elderly (RD at 2 years: 76% vs 36%, P = .015). ASCT increased the proportion of patients in MR from 55% before high-dose therapy to 72% thereafter. Sequential MRD monitoring is a powerful predictor for treatment outcome in MCL. These trials are registered at www.clinicaltrials.gov as #NCT00209222 and #NCT00209209.

[1]  E. Hoster,et al.  Improvement of overall survival in advanced stage mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Hagenbeek,et al.  High‐dose Ara‐C and beam with autograft rescue in R‐CHOP responsive mantle cell lymphoma patients , 2009, British journal of haematology.

[3]  G. Salles,et al.  RCHOP and RDHAP Followed by Autologous Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL) : Final Results of a Phase II Study from the GELA , 2008 .

[4]  H. Döhner,et al.  Quantitative MRD Assessments Predict Progression Free Survival in CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab – a Prospective Analysis in 471 Patients from the Randomized GCLLSG CLL8 Trial , 2008 .

[5]  E. Kimby,et al.  Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. , 2008, Blood.

[6]  N. Schmitz,et al.  Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial , 2008, Leukemia.

[7]  A. Levis,et al.  Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. , 2008, Blood.

[8]  W. Klapper,et al.  Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations , 2008, Haematologica.

[9]  E. Giné,et al.  Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication , 2008, Clinical Cancer Research.

[10]  E. Hoster,et al.  European MCL network: An update on current first line trials , 2007 .

[11]  J. Cayuela,et al.  Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data , 2007, Leukemia.

[12]  Martin Dreyling,et al.  A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. , 2006, Blood.

[13]  J. Szer,et al.  The hyper-CVAD–rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma , 2006, Annals of Hematology.

[14]  R. Siebert,et al.  Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. , 2006, Blood.

[15]  L. Staudt,et al.  Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. , 2005, Blood.

[16]  Michael L. Wang,et al.  High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Fegan,et al.  Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Hoster,et al.  Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  E. Hoster,et al.  Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. , 2004, Blood.

[20]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M Hummel,et al.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 , 2003, Leukemia.

[22]  K. Franssila,et al.  Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant , 2003, European journal of haematology.

[23]  T. Barbui,et al.  Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). , 2003, Blood.

[24]  D. Weisenburger,et al.  Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries , 2003, British journal of haematology.

[25]  T. Chisesi,et al.  High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). , 2002, Blood.

[26]  E. Kimby,et al.  Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). , 2002, Blood.

[27]  J. Gribben,et al.  Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma. , 2002, Experimental hematology.

[28]  J. Gribben,et al.  Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  G. Morgan,et al.  Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. , 2001, Blood.

[30]  H. Kantarjian,et al.  Untreated Aggressive Mantle Cell Lymphoma: Results with Intensive Chemotherapy without Stem Cell Transplant in Elderly Patients , 2000, Leukemia & lymphoma.

[31]  C. V. D. Schoot,et al.  Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes , 1998, Leukemia.

[32]  H. Kantarjian,et al.  Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Tiemann,et al.  Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas , 1998, Leukemia.

[34]  R. Siebert,et al.  Application of interphase cytogenetics for the detection of t(11;14)(q13;q32) in mantle cell lymphomas. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  J. Gribben,et al.  Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. , 1997, Blood.

[36]  N. Schmitz,et al.  Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  A. Pileri,et al.  Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. , 1997, Blood.

[38]  A. Pileri,et al.  Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle‐cell lymphoma , 1996, British journal of haematology.

[39]  M. Engelhard,et al.  Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis , 1989, Hematological oncology.

[40]  L. Lin,et al.  A concordance correlation coefficient to evaluate reproducibility. , 1989, Biometrics.

[41]  N. Schmitz,et al.  Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. , 2007, Haematologica.

[42]  L. Staudt,et al.  Cyclin D 1 – negative mantle cell lymphoma : a clinicopathologic study based on gene expression profiling , 2005 .

[43]  A. Delmer,et al.  Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. , 2004, Haematologica.